Veteran Pharma VC Insider Buys 25,000 Nuvation Bio Shares as New Drug Gains Momentum

Robert Mashal, an oncology-trained director at Nuvation Bio, purchased 25,000 shares at $4.73 per share on June 9, 2026, bringing his total indirect holdings to 225,000 shares. The purchase comes as Nuvation's first FDA-approved cancer drug, Ibtrozi, continues gaining traction with over 200 new patients per quarter since its July 2025 launch. The stock has surged 96% over the past year, and Wall Street projects revenue will nearly triple to $203 million in 2026.